PAM
NRIX icon

Panagora Asset Management’s Nurix Therapeutics NRIX Stock Holding History

Panagora Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-18,171
Closed -$143K – 1271
2023
Q3 		$143K Sell
18,171
-70,911
-80% -$647K ﹤0.01% 1195
2023
Q2 		$890K Sell
89,082
-455
-0.5% -$4.64K 0.01% 823
2023
Q1 		$795K Buy
89,537
+59,173
+195% +$617K 0.01% 931
2022
Q4 		$333K Buy
+30,364
New +$366K ﹤0.01% 1259

Other funds holding NRIX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Panagora Asset Management's NRIX Position: Q4 2023 in Review

Panagora Asset Management sold out of Nurix Therapeutics (NRIX) in Q4 2023, closing a stake of 18,171 shares — an estimated $143K sold.

Panagora Asset Management first reported a position in NRIX in Q4 2022 and held it in 4 quarters. The position peaked at $890K in Q2 2023. 130 funds tracked by Wall St. Rank hold NRIX as of Q4 2023.

  • Panagora Asset Management reported no remaining Nurix Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Panagora Asset Management sold 18,171 Nurix Therapeutics shares in Q4 2023, an estimated $143K.
  • Panagora Asset Management first reported a position in Nurix Therapeutics in Q4 2022 and held it in 4 quarters.
  • Panagora Asset Management's Nurix Therapeutics position peaked at $890K in Q2 2023.
  • 130 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2023.

Based on Panagora Asset Management's 13F filing for Q4 2023, filed 8 Feb 2024.